# Neurology (multiple sclerosis) Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

- To: Kenji Watanabe, MD, Neurology (multiple sclerosis)
- Urgency: Within two weeks, on the same day as her two-week primary care visit

## Referral question

Multiple sclerosis diagnosed elsewhere in a 44-year-old professor and public speaker who walks with a cane, with records of the original evaluation not available. Please confirm and classify the disease on the MRI booked for the morning of your visit, and advise on disease-modifying therapy, its screening and monitoring, vaccination, symptom care and MRI follow-up. **S**

## Questions for the consultant

1. Does she meet the 2017 McDonald criteria, and is her course relapsing or progressive, active or not active?
2. Which disease-modifying therapy, if any, do you advise, and why?
3. What screening and vaccination are needed before the first dose, and how long before?
4. What monitoring will the therapy need?
5. When should the MRI be repeated, and with what protocol?
6. What do you advise for spasticity, bladder urgency, fatigue and heat sensitivity?
7. How should she recognize and report a relapse?

## Pertinent history

By her account multiple sclerosis was diagnosed elsewhere some years ago; she has no records and recalls no attack that came on over days and recovered. Her walking has worsened slowly over the past few years: she began using a cane while still in her previous public office, and now rests after about 100 meters. Leg stiffness, afternoon fatigue, heat sensitivity, urinary urgency and nocturia twice. Two near-falls and no falls in the past year. No previous disease-modifying therapy; she recalls steroid courses in the past. Today: blood pressure 124/78, weight 84.0 kg, BMI 28.1; spastic paraparetic gait with a cane; post-void residual 40 mL by bladder scan; PHQ-9 6. Results today: white cells 6.4, lymphocytes 1.9, hemoglobin 13.2 g/dL, platelets 262; creatinine 0.78 mg/dL, eGFR 96; ALT 18, AST 20, alkaline phosphatase 72 U/L, bilirubin 0.5 mg/dL; TSH 1.8; vitamin B12 520 pg/mL; 25-hydroxyvitamin D 17 ng/mL, so vitamin D3 started; IgG 1080, IgM 110, IgA 210 mg/dL; JC virus antibody index 0.14. Hepatitis B serology, varicella and measles immunity, tuberculosis blood test, HIV and hepatitis C are pending. MRI of the brain and cervical and thoracic spine with gadolinium is booked for the morning of your visit. She keeps her diagnosis private and decides who receives this letter. **S**

- Barbara Jordan was born on February 21, 1936, in Houston, Texas, the youngest of three daughters, and grew up in Houston's Fifth Ward. She graduated magna cum laude from Texas Southern University in 1956 and earned a law degree from Boston University in 1959. **D**
- In 1966 she was elected to the Texas Senate, the first Black state senator since 1883. In 1972 she was elected to the U.S. House of Representatives from Houston, the first Black woman from a Southern state to serve in Congress. As a member of the House Judiciary Committee during the 1974 impeachment hearings she said, "My faith in the Constitution is whole, it is complete, it is total." **D**
- In 1976 she gave the keynote address at the Democratic National Convention, the first woman and the first African American to do so. **D**
- She did not seek a fourth term and left the House in 1979, downplaying reports about her poor health and citing her "internal compass." She became the Lyndon Baines Johnson Public Service Professor at the LBJ School of Public Affairs of the University of Texas at Austin, where she taught until the early 1990s. **D**
- In her later years in the House she walked with a cane, which she attributed at the time to "a bum knee"; a disability-press account written after her death says this was the first adaptive equipment her multiple sclerosis required, and that she did not openly acknowledge the disease for years. **D**
- It was later revealed that she had been diagnosed with multiple sclerosis around the time she left Congress. The year of the diagnosis is not stated in the obituaries and reference works consulted. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: White cells: 6.4 10*3/uL; Lymphocytes (absolute): 1.9 10*3/uL; Hemoglobin: 13.2 g/dL; Platelets: 262 10*3/uL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 2021): 96 mL/min/1.73 m²; ALT: 18 U/L; AST: 20 U/L; Alkaline phosphatase: 72 U/L; Total bilirubin: 0.5 mg/dL; TSH: 1.8 mIU/L; Vitamin B12: 520 pg/mL; 25-hydroxyvitamin D: 17 ng/mL (low); IgG: 1080 mg/dL; IgM: 110 mg/dL; IgA: 210 mg/dL; JC virus antibody index: 0.14; PHQ-9: 6. All results are synthetic.

BP 124/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 84 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Current medications

- Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**

## Plan so far

- Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 2017 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation. Guideline: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); Adult Immunization Schedule by Age (2026) **S**
- Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Multiple sclerosis in adults: management (NG220) (2022) **S**
- Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose. Guideline: Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026) **S**
- Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time. Guideline: Multiple sclerosis in adults: management (NG220) (2022); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
